By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cubist Pharmaceuticals, Inc. 

65 Hayden Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-8660 Fax: 781-861-0566

There’s something special about working at Cubist Pharmaceuticals.

We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.

Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).

Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.

Key Statistics

Ownership: Public

Web Site: Cubist
Employees: ~600
Symbol: MRK

Company News
Former Cubist (MRK) CEO, Dreamworks Interactive CEO, And Google (GOOG) Chief Game Designer Team-Up With Akili Interactive To Advance Digital Medicine Product Portfolio 6/28/2017 6:32:46 AM
Booming Shire (SHPG) Expands Massachusetts Footprint by Leasing Two Ex-Cubist (MRK) Buildings 3/11/2016 3:10:04 PM
Dosing Errors With Cubist (MRK) Antibiotic Prompt FDA Warning 5/22/2015 6:39:08 AM
Cubist (MRK) Employees Have Been Looking for New Jobs the Past Three Months, Says Staffing Firms 3/9/2015 6:33:03 AM
Merck & Co. (MRK) to Slash 120 Staffers at Newly-Acquired Cubist (MRK) Drug Discovery Unit 3/5/2015 3:54:44 PM
Merck & Co. (MRK), On Behalf Of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Inc. (CBST), Announces Results Of Tender Offer For Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 And 1.875% Convertible Senior Notes Due 2020 2/24/2015 11:49:03 AM
Merck & Co. (MRK), On Behalf Of Its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Inc. (CBST), Announces Tender Offer For Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 And 1.875% Convertible Senior Notes Due 2020 1/23/2015 10:38:27 AM
Merck & Co. (MRK) Completes Tender Offer To Acquire Cubist Pharmaceuticals, Inc. (CBST) 1/21/2015 8:15:20 AM
Cubist Pharmaceuticals, Inc. (CBST) Announces Withdrawal Of Listing Of CVRs (CBSTZ) From NASDAQ Global Select Market 1/13/2015 7:42:38 AM
Cubist Pharmaceuticals, Inc. (CBST) Announces FDA Approval Of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) For Complicated Urinary Tract And Complicated Intra-abdominal Infections 12/22/2014 11:55:37 AM